Assignee
PHARMACOSMOS HOLDING AS
DK26 patents
Top patents by PatentIndex Score
US9439969B2Sep 13, 2016
Stable iron oligosaccharide compound
PHARMACOSMOS HOLDING AS16 citations91
US6977249B1Dec 20, 2005
Process for producing an iron-dextran compound, iron-dextran compound produced according to said process, pharmaceutical composition for prophylaxis or treatment of iron-deficiency and use of said compound for the preparation of parenterally administrable pharmaceutical composition
PHARMACOSMOS HOLDING AS35 citations89
US6291440B1Sep 18, 2001
Iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency
PHARMACOSMOS HOLDING AS30 citations89
US10414831B2Sep 17, 2019
Stable iron oligosaccharide compound
PHARMACOSMOS HOLDING AS6 citations82
US11020369B2Jun 1, 2021
Treating iron deficiency with ferric carboxymaltose
PHARMACOSMOS HOLDING AS5 citations79
US12364697B2Jul 22, 2025
G1T38 superior dosage regimes
PHARMACOSMOS HOLDING AS4 citations71
US12030962B2Jul 9, 2024
Stable iron oligosaccharide compound
PHARMACOSMOS HOLDING AS1 citations71
US11851504B2Dec 26, 2023
Stable iron oligosaccharide compound
PHARMACOSMOS HOLDING AS2 citations71
US10865255B2Dec 15, 2020
Stable iron oligosaccharide compound
PHARMACOSMOS HOLDING AS1 citations71
US12264135B2Apr 1, 2025
Synthesis of 1,4-diazaspiro[5.5]undecan-3-one
PHARMACOSMOS HOLDING AS3 citations69
US11806329B2Nov 7, 2023
Treating iron deficiency with ferric carboxymaltose
PHARMACOSMOS HOLDING AS3 citations68
US11111261B2Sep 7, 2021
Iron complex compounds for therapeutic use
PHARMACOSMOS HOLDING AS2 citations66
US11040059B2Jun 22, 2021
Treatment or prevention of anaemia in pregnant non-human mammals
PHARMACOSMOS HOLDING AS2 citations66
US12565502B2Mar 3, 2026
Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c] [1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors
PHARMACOSMOS HOLDING AS0 citations62
US12312360B2May 27, 2025
Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors
PHARMACOSMOS HOLDING AS0 citations62
US12534472B2Jan 27, 2026
Morphic forms of trilaciclib and methods of manufacture thereof
PHARMACOSMOS HOLDING AS0 citations61
US12497404B2Dec 16, 2025
Morphic forms of trilaciclib and methods of manufacture thereof
PHARMACOSMOS HOLDING AS0 citations61
US12479855B2Nov 25, 2025
Morphic forms of trilaciclib and methods of manufacture thereof
PHARMACOSMOS HOLDING AS0 citations61
US12527798B2Jan 20, 2026
Preservation of immune response during chemotherapy regimens
PHARMACOSMOS HOLDING AS0 citations59
US11633489B2Apr 25, 2023
Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant
PHARMACOSMOS HOLDING AS1 citations59
US11471483B2Oct 18, 2022
Iron carbohydrate complex for treatment of restless leg syndrome (RLS)
PHARMACOSMOS HOLDING AS1 citations59
US11040064B2Jun 22, 2021
Iron carbohydrate complex for treatment of restless leg syndrome (RLS)
PHARMACOSMOS HOLDING AS1 citations59
US10960081B2Mar 30, 2021
Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant
PHARMACOSMOS HOLDING AS1 citations59
US12303486B2May 20, 2025
Treating iron deficiency with ferric carboxymaltose
PHARMACOSMOS HOLDING AS0 citations57
US12295934B2May 13, 2025
Treating iron deficiency with ferric carboxymaltose
PHARMACOSMOS HOLDING AS0 citations57
US11484025B2Nov 1, 2022
Cryoprotecting agent, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation
PHARMACOSMOS HOLDING AS1 citations51